Genmab A/S (OTCMKTS:GNMSF) Short Interest Down 20.5% in January

Genmab A/S (OTCMKTS:GNMSF) saw a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 80,900 shares, a decline of 20.5% from the January 15th total of 101,800 shares. Based on an average daily trading volume, of 21,300 shares, the days-to-cover ratio is presently 3.8 days.

Genmab A/S Stock Performance

OTCMKTS:GNMSF traded up $3.35 during mid-day trading on Monday, reaching $210.97. The stock had a trading volume of 157 shares, compared to its average volume of 6,895. Genmab A/S has a one year low of $186.61 and a one year high of $323.02. The firm has a 50 day moving average price of $206.25 and a two-hundred day moving average price of $229.26. The stock has a market capitalization of $13.94 billion, a P/E ratio of 20.29 and a beta of 1.04.

Genmab A/S (OTCMKTS:GNMSF) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $5.70 earnings per share for the quarter, beating the consensus estimate of $0.46 by $5.24. Genmab A/S had a return on equity of 17.73% and a net margin of 23.49%.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.